About this trial
Anxiety and depression symptoms occur at high rates in Veteran populations and can significantly impact function, compromising the ability to work and to successfully form and maintain valued relationships. Several other symptoms commonly occur with anxiety and depression, including poor sleep quality and chronic pain. Since all these symptoms frequently occur together, they may have a common underlying biological basis. A single medication that could effectively treat all these symptoms would be ideal. Converging data suggest that pregnenolone is a promising pharmacological agent for treating multiple psychiatric symptoms and functional impairment. The investigators thus propose to conduct a clinical trial of pregnenolone in Veterans with anxiety and depression symptoms. Pregnenolone has minimal side effects, and the prior research demonstrates that pregnenolone is well-tolerated by Veterans. Treatment with pregnenolone could thus be an efficacious new therapeutic for Veterans experiencing depression, anxiety, poor sleep quality and chronic pain conditions.
Eligibility criteria
Qualifiers
Veterans enrolled for care at the Durham VAHCS
Veterans who score a minimum score of 20 or higher (moderate symptoms) on the PHQ-ADS (Kroenke et al 2017)
Oral pregnenolone could reduce the effectiveness of oral contraceptives, thus women will be required to use a medically and study-approved contraceptive or otherwise not be of child-bearing potential. Birth control methods must be non-hormonal
No anticipated need to alter psychiatric medications for duration of study involvement
Disqualifiers
History of allergy to PREG
Medical disorders that may preclude safe administration of PREG or exacerbate mental or physical health symptoms
PTSD diagnosis, as per the PCL-5, scores of 38 or higher
Current suicidal or homicidal ideation necessitating clinical intervention or representing an imminent concern
Trial design
Treatments tested in this trial
- Pregnenolone
- Placebo